A 42-year-old man with a 15-year history of ulcerative colitis presents with progressive pruritus, jaundice, and fatigue. Liver function tests show elevated alkaline phosphatase (ALP 280 U/L) and gamma-glutamyl transferase (GGT 320 U/L) with mild hyperbilirubinemia. MRCP reveals the characteristic finding marked as **C** in the diagram — multiple strictures of intra- and extrahepatic bile ducts with intervening dilatations creating a "beaded" or "string of beads" appearance. Which of the following statements best reflects the clinical significance of this finding in the context of his ulcerative colitis?

Explanation

## Why option 2 is right Primary sclerosing cholangitis (PSC), marked as **C**, is a chronic inflammatory disease of bile ducts characterized by strictures and dilatations creating the pathognomonic "beaded" or "string of beads" appearance on MRCP. Critically, PSC occurs **independently of bowel activity** — meaning medical optimization of colitis does not prevent or reverse PSC progression. The anchor fact is that PSC carries a **markedly elevated lifetime risk of cholangiocarcinoma (10-15%)**, necessitating annual MRCP imaging and CA 19-9 monitoring. Additionally, UC patients with PSC have higher colorectal cancer risk than UC alone, requiring annual colonoscopy with biopsies. While ~75% of PSC patients have IBD (predominantly UC), only ~5% of UC patients develop PSC. No medical therapy halts PSC progression; liver transplant is the only definitive treatment. ## Why each distractor is wrong - **Option 1 (tracks with bowel activity; resolves with anti-TNF/5-ASA)**: This describes erythema nodosum (marked **A**), which IS activity-dependent and improves with bowel disease control. PSC is independent of bowel activity and does NOT respond to medical IBD therapy. This is a critical clinical distinction. - **Option 3 (more common in Crohn; acute cholangitis presentation)**: PSC is more strongly associated with ulcerative colitis than Crohn disease. While acute cholangitis can occur, the question emphasizes the chronic "beaded" appearance and surveillance implications, not acute presentation. This distractor conflates PSC with other biliary complications. - **Option 4 (pathognomonic for UC; develops in 30-40%)**: PSC is NOT pathognomonic for UC (it can occur in other conditions and even without IBD). Only ~5% of UC patients develop PSC, not 30-40%. Colectomy does not prevent PSC progression or eliminate cancer risk in the transplanted liver. **High-Yield:** PSC in UC is **activity-independent**, carries **10-15% cholangiocarcinoma risk**, and requires **annual MRCP + CA 19-9 surveillance** — no medical therapy halts progression; liver transplant is definitive but PSC recurs in ~20% of grafts. [cite: Robbins 10e Ch 17, Ch 18; Harrison 21e Ch 343]